IQVIA Holdings, Inc.

  • Market Cap: Mid Cap
  • Industry: Miscellaneous
  • ISIN: US46266C1053
USD
224.92
-2.32 (-1.02%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About IQVIA Holdings, Inc. stock-summary
stock-summary
IQVIA Holdings, Inc.
Miscellaneous
IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.
Company Coordinates stock-summary
Company Details
4820 Emperor Blvd , DURHAM NC : 27703-8426
stock-summary
Tel: 1 919 9982000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 168 Schemes (34.46%)

Foreign Institutions

Held by 463 Foreign Institutions (27.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Ari Bousbib
Chairman of the Board, President, Chief Executive Officer
Dr. John Leonard
Lead Independent Director
Ms. Carol Burt
Independent Director
Mr. John Connaughton
Independent Director
Mr. John Danhakl
Independent Director
Mr. James Fasano
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
4,015 Million
(Quarterly Results - Jun 2025)
Net Profit:
266 Million
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 47,314 Million (Mid Cap)

stock-summary
P/E

29.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

2.30

stock-summary
Return on Equity

22.50%

stock-summary
Price to Book

8.19